<div id="readability-page-1"><p>Bar Harbor Wealth Management cut its holdings in shares of  Eli Lilly and Company (NYSE:LLY - Free Report) by 3.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor  owned 72,327 shares of the company's stock after selling 2,647 shares during the period. Eli Lilly and Company accounts for  3.3% of Bar Harbor Wealth Management's holdings, making the stock its 5th biggest holding. Bar Harbor Wealth Management's holdings in Eli Lilly and Company were worth $55,186,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li></ul><p>A number of other large investors also recently bought and sold shares of the business. Braun Bostich &amp; Associates Inc. increased its holdings in shares of  Eli Lilly and Company by 2.5% in the 2nd quarter. Braun Bostich &amp; Associates Inc. now owns 527 shares of the company's stock valued at $411,000 after acquiring an additional 13 shares during the period.  Rise Advisors LLC lifted its stake in shares of  Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after purchasing an additional 13 shares during the last quarter.  Occidental Asset Management LLC boosted its position in  Eli Lilly and Company by 0.7% during the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock valued at $1,533,000 after purchasing an additional 13 shares in the last quarter.  New Insight Wealth Advisors grew its stake in  Eli Lilly and Company by 3.4% in the second quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock valued at $307,000 after purchasing an additional 13 shares during the last quarter.  Finally, Dash Acquisitions Inc. grew its stake in  Eli Lilly and Company by 2.8% in the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock valued at $387,000 after purchasing an additional 13 shares during the last quarter. Institutional investors own  82.53% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research firms have commented on LLY. HSBC  reissued a &#34;hold&#34; rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Daiwa Capital Markets  set a $1,230.00 target price on shares of Eli Lilly and Company and gave the company a &#34;buy&#34; rating in a research report on Tuesday, December 16th. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, November 24th. Leerink Partners  reaffirmed an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a research report on Thursday, December 18th. Finally, Wolfe Research increased their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, December 3rd. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued  a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $1,155.36.</p><ul><li>Sector Rotation: 2 Smart Money Moves for 2026</li></ul><p><b>View Our Latest Report on LLY</b></p><h2>Eli Lilly and Company Trading Up 0.0%</h2><p>NYSE:LLY opened at $1,077.26 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The firm has a fifty day simple moving average of $986.75 and a 200-day simple moving average of $841.14. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $1.02 trillion, a P/E ratio of 52.70, a PEG ratio of 1.09 and a beta of 0.37. </p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm's revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.  On average, equities research analysts anticipate that  Eli Lilly and Company will post 23.48 earnings per share for the current year. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company's dividend payout ratio  is currently 33.86%. </p><h2>About Eli Lilly and Company</h2> (Free Report)<p>Eli Lilly and Company <span>NYSE: LLY<span></span></span> is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bar Harbor Wealth Management reduced its holdings in Eli Lilly and Company by 3.5% in Q3, now owning 72,327 shares worth $55.19 million, making it the firm's 5th largest position. Other investors also adjusted their holdings. Analysts have given Eli Lilly a consensus rating of 'Moderate Buy' with a target price of $1,155.36. The company's recent earnings beat estimates with $7.02 EPS and $17.60 billion in revenue, showing a 53.9% year-over-year increase.</p>

Eli Lilly and Company $LLY is Bar Harbor Wealth Management's 5th Largest Position